Anticoagulation Management for Newly Diagnosed Atrial Fibrillation

Initial Risk Assessment

The European Society of Cardiology recommends assessing stroke risk using the CHA₂DS₂-VASc score to guide anticoagulation decisions, with a score of ≥2 in men or ≥3 in women indicating strong recommendation for anticoagulation 1, 2
The American Heart Association suggests evaluating bleeding risk by identifying modifiable risk factors, but advises against using bleeding risk scores to withhold anticoagulation 1

The European Heart Journal recommends direct oral anticoagulants (DOACs) over warfarin for eligible patients with non-valvular atrial fibrillation, due to their superior effectiveness and safety profile 1, 2, 3
The American College of Chest Physicians notes that DOACs demonstrate significantly less major bleeding compared to warfarin, particularly intracranial hemorrhage 3
For patients with mechanical heart valves or moderate-to-severe mitral stenosis, the European Society of Cardiology recommends warfarin as the only option, with a target INR of 2.0-3.0 1
The American College of Chest Physicians suggests that for patients with prior gastrointestinal bleeding, apixaban or dabigatran 110mg may be preferable as they have not shown increased risk of GI bleeding compared to warfarin 3

The American College of Chest Physicians recommends targeting an INR of 2.0-3.0 for warfarin, with attention to individual time in therapeutic range (TTR), ideally ≥70% 3
The European Heart Journal suggests using standard dosing for stroke prevention with DOACs, with reduced doses only when meeting specific criteria for each agent 1
The American Heart Association recommends evaluating renal and hepatic function before starting a DOAC and at least annually thereafter 2

The American College of Chest Physicians recommends starting therapeutic anticoagulation at presentation and proceeding with cardioversion for AF duration ≤48 hours, with continuation of anticoagulation for at least 4 weeks after successful cardioversion 4
For AF with hemodynamic instability requiring urgent cardioversion, the American College of Chest Physicians suggests starting therapeutic-dose parenteral anticoagulation before cardioversion if possible, but not delaying emergency intervention, and continuing therapeutic anticoagulation for at least 4 weeks regardless of baseline stroke risk 4

The American College of Chest Physicians recommends decisions about anticoagulation beyond 4 weeks post-cardioversion be based on the patient's CHA₂DS₂-VASc risk profile, not on whether sinus rhythm was restored 4
The American Heart Association suggests regular reassessment of stroke and bleeding risks to guide ongoing anticoagulation therapy 2

The American College of Chest Physicians advises against using aspirin alone or in combination with clopidogrel for stroke prevention in AF 3
The European Heart Journal recommends avoiding underdosing of DOACs by using reduced doses unless patients meet specific criteria for dose reduction 1
The European Heart Journal also advises against switching between DOACs without clear indication, as this does not reduce recurrent embolic stroke risk 1
The European Heart Journal suggests not delaying cardioversion in hemodynamically unstable patients to achieve therapeutic anticoagulation 1